- McKesson’s Adjusted EPS, a key profitability metric, came in at $6.18, lower than estimates of $6.31 and last year’s performance of $7.19.
- Total revenue reported was $76.36 billion, a growth of 11% from last year, but fell short of estimated revenue of $79.17 billion.
- The US pharmaceutical revenue, a main contributor, was $68.79 billion, marking a 12% increase compared to last year, but didn’t meet the estimate of $72.82 billion.
- McKesson’s international revenue surpassed estimates, reaching a total of $3.55 billion, up 5.5% from the previous year.
- The revenue from medical-surgical solutions amounted to $2.84 billion, up 5.5% on a yearly basis, slightly surpassing expectations of $2.76 billion.
- The company’s prescription technology solutions sector reported a slight decrease in revenue from the last year at $1.18 billion, missing the estimate of $1.29 billion.
- From an analyst perspective, most have a positive outlook with 16 buy ratings, 2 hold ratings, and just 1 sell rating.
Mckesson Corp on Smartkarma
Analyst coverage of McKesson Corp on Smartkarma by Baptista Research showcases a positive sentiment towards the company’s performance. In their report titled “McKesson Corporation: Anticipated Revenue Growth in Medical-Surgical Solutions Could Propel Them Forward! – Major Drivers,” Baptista Research highlights McKesson’s robust fiscal third-quarter earnings, with total revenues of $80.9 billion and adjusted earnings per diluted share of $7.74 showing impressive double-digit growth year over year. The report commends McKesson’s focused execution against long-term priorities as a key driver of their strong financial performance.
In another insightful report titled “McKesson Corporation: How Their Biopharma Platform is Redefining Industry Standards! – Major Drivers,” Baptista Research continues to emphasize McKesson’s outperformance, exceeding revenue and earnings expectations in the second quarter. The Distribution business, especially in the US Pharmaceutical segment, is recognized for consistently achieving double-digit revenue increases over the past ten quarters. Overall, the analyst coverage on Smartkarma reflects confidence in McKesson Corp’s strategic initiatives and financial trajectory.
A look at Mckesson Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
McKesson Corp, a key player in the distribution of healthcare products and provider of data integration software in North America, has received positive Smartkarma Smart Scores across various factors. With top marks in Growth, Resilience, and Momentum, the company’s long-term outlook appears promising. This signifies its potential for robust and sustained growth, solid ability to withstand challenges, and a strong upward trend in performance.
Although McKesson Corp scored lower on the Value factor, its high ratings in Dividend, Growth, Resilience, and Momentum highlight the company’s overall strength and potential for future profitability. Investors may find confidence in the company’s consistent performance and strategic positioning within the healthcare distribution and software integration sectors in North America.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
